This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
We cannot change the fact that some patients must take multiple drugs, but we can certainly change how we manage it with careful coordination and communication among healthcareproviders, and personalized medicine practices such as pharmacogenomics.
As multi-billion investment continues to pour into the R&D of future obesity medications, the need for evidence generation of health benefits beyond short-term weight loss will be critical to the decision-making of healthcareproviders and payers. appeared first on MedCity News.
For patients who may be unable to afford the high cost of GLP-1 obesity drugs or are worried about the side effects, it’s important for healthcareproviders to offer education on herbal alternatives and consider these as part of the broader treatment conversation. appeared first on MedCity News.
Science has taken a vertical growth trajectory, yet such innovations are, at best, slow to reach the patients in need. We believe that innovation in patient access models is the necessary catalyst to aid patients in starting on and staying on the therapies they need to improve their lives.
The goal was simple: provide access and focused support to patients remotely while simultaneously relieving overtaxed healthcare facilities. Combined, DTx and DCTs improve patient recruitment, retention, and access, allowing researchers to pull from underserved communities, including rural populations.
Biopharma blockbusters in the last 10 years show a disturbing trend. As a top 10 biopharma company leader shared with us, “Real blockbusters are gone. Despite the rapid advances that have enabled these innovations, healthcare systems and commercial infrastructure aren’t keeping pace. In oncology, it’s 47% less.
From connecting with patients by interactive ads to dabbling into cross-platform integration, here is what our specialists had to say. What are new and effective ways of engaging patients who are now using streaming services? Biopharma marketers are following their audiences and investment in this channel continues to increase.
Bryan Johnson Senior Director, Product Management, Compass Prescriber Veeva Systems Paving the Way to Faster Treatment Starts Bryan’s exposure to life sciences started at a young age, watching his father’s career at companies like Johnson & Johnson and emerging biopharmas. As rare diseases affect about 1 in 10 people in the U.S.,
This fuels an enormous need for effective patient communication and education as new therapies move through the biopharma pipeline. Marketing to rare disease patient populations is equal parts opportunity and responsibility. audiences (direct-to-patient advertising rules are fundamentally different overseas).
In fact, for the past five years, the number of treated patients with cancer has seen an average annual increase of 5% globally (1). This competitive intensity tends to focus on smaller patient populations with multiple treatment options (1,2). However, with rapid growth comes growing pains.
Powered by the company’s customer relationship management system, the CGT integration hub is a platform-agnostic system that aims to improve connectivity across the CGT treatment journey, enhancing the experience for patients and healthcareproviders.
Only 5% of patients ranked pharma companies as the most trusted player in the healthcare space, according to a 2021 survey of 500 patients from Accenture. But 71% also want publicly shared information about how patients’ perspectives were incorporated into the development of products and services. Noël Moossa.
Novo Nordisk and Avalere Health NovoCare has redefined patient support with its advanced coverage check tool, streamlining the overwhelming process of understanding treatment costs and insurance coverage. FINALISTS: Crack the JAK (Scientific Global) Don’t Sweat Inventory Management (Accord Biopharma, Inc. &
As professionals with more than a half-century between us working in biopharma and diagnostics marketing and communications from the corporate (Ayaz Malik) and agency (Sandra Stahl) sides, we believe nurturing multigenerational teams is an especially powerful yet underutilized strategy for our industry.
The time-consuming and resource-intensive path from the lab bench to the patient bedside starts with drug discovery, progresses to pre-clinical and clinical research, and then enters regulatory review. Any misstep in terms of pricing, reimbursement, or marketing could mean delays in providing therapies to the patients who need them most.
AstraZeneca’s first-in-class severe asthma therapy Tezspire has been approved in the EU in a new pen injector formulation suitable for administration by patients themselves. million patients worldwide with severe asthma who are uncontrolled, without any phenotypic and biomarker limitation.
Ittai Dayan , Co-founder & CEO of Rhino Health , will join Natalie Yeadon , Co-founder & CEO of Impetus Digital , to share how his company is transforming the way healthcare AI solutions are created, adopted and measured. Register now! Register for this free webinar. About Impetus Digital. Book a Consultative Demo.
LHON mutation rate variability affects therapeutic efficacy Most LHON patients carry one of three pathogenic mitochondrial DNA mutations (11778G>A [ND4], 14484T>C [ND6] and 3460G>A [ND1]) known as primary LHON mutations. We identified patients with an LHON diagnosis using ICD-10 and ICD-9 codes H47.2 The Clarivate U.S.
PaceMate ® announced today its collaboration with AliveCor ® , the global leader in FDA-cleared personal electrocardiogram technology and remote patient management solutions for the cardiovascular industry. We are proud to be the pioneer in remote cardiac management.”
However, due to conjugation instability and unfavorable safety profiles of currently available ADCs, we can still do more to ensure ADCs are more broadly available and amenable options for the patients who need them. Cellectis is pioneering the concept of off-the-shelf and ready-to-use gene-edited CAR T-cells to treat cancer patients.
In this issue, we take a closer look on the importance of patient education to Healthcare Professionals and navigating the challenges that arise. ABIGAIL MALLON Chief Patient Experience Officer, VMS BioMarketing Physician burnout is on the rise. The second to increase in patient-oriented communication and support for physicians.
Today’s physicians struggle to balance the increasing demands of patient loads, electronic health record (EHR) systems, and time spent on administrative tasks. 2 The percentage of healthcareproviders willing to see pharmaceutical company reps in person had declined from 67% in 2018 to 54% in 2019.
In this issue, we take a closer look at adherence and compliance regarding patients and medications along with their involvement with pharmaceutical companies. What strategies are most effective in improving patient adherence to prescribed medication regimens, and how can pharmaceutical companies support these strategies?
Reading time: 4 minutes A patient support network isn’t made up of just doctors or nurses. Through contracting with pharmaceutical and biotech companies, VMS BioMarketing provides clinical educator solutions focused on empowering healthcareproviders and patients through product support, education, and training.
We’re gaining a richer understanding of the brain’s complex inner workings, and today’s innovations reveal the vast, untapped potential of science and technology to transform the lives of patients and their families. Regarding leadership, my guiding principle has always been to do what’s right for patients and your people.
Ittai Dayan , Co-founder & CEO of Rhino Health , shared how his company is transforming the way healthcare AI solutions are created, adopted and measured. For example, taking a patient registry, you work on re-structured data and then add to that, imaging data.
Health systems will buy or establish an insurance plan to serve as an extension of their continuum of care, a means of directing referral streams to increase revenue and securing control over clinical and formulary decisions for patients.
In the pharmaceutical sector, this evolved further with privacycompliant data enrichment, enabling hyper-personalized messaging for healthcareproviders (HCPs). Stronger brand consistency, improved rep performance, and better business and patient outcomes. The result? References 1. Veeva Pulse Field Trends Report, 2023 2.
A New Online Destination for HCPs HealthCentral Corporation , operator of leading digital platforms that serve patients living with chronic illness, their care partners, and health professionals, has announced the newest addition to its suite of HCP support sites: MedCentral.
Biosimilars: The Future of Affordable Biologic Therapies Biologics are some of the most expensive forms of therapy in modern healthcare. However, there are products that can help bridge the affordability gap created by these biologics, while also providing similar efficacy and safety for patient treatment.
Each of their trailblazing efforts result in much more than personal or organization success, it results in better quality of life for patients, better care options for healthcareproviders, and happier and healthier people around the world.” Director US Marketing and Patient Engagement, argenx US, Inc.
Manufacturers, healthcareproviders, and consumers alike face the need to quickly adapt. A chance to innovate: Global health impacts our world and there are various stakeholders making choices, from manufacturers to healthcareproviders and patients. Impending change affords an opportunity for innovation.
healthcare provision landscape, integrated delivery networks, or IDNs, are differentiating their offerings by adding outpatient treatment centers, pursuing National Cancer Institute designations and investing in value-based care. states and the United Kingdom and sees more than 35 million patient encounters per year.
Furthermore, entire value chains must be redesigned and the CO 2 emitters (especially point source emitters), chemical industry and power sector, downstream users, eg, healthcare industries and their customers, and healthcareproviders need to be coordinated, informed, sensitised and must work out contractual frameworks to de-risk the investments.
Patient support programs (PSPs) are meant to do just that. We asked: • What unique considerations should be taken into account when designing patient support programs (PSPs) for niche populations with rare diseases? • How can we enhance patient engagement in rare disease support programs?
The capabilities of Viroclinics and DDL allowed us to rapidly test repurposed drugs, new vaccines and antiviral solutions for the prevention and treatment of patients affected by COVID-19 in 2020. A lot of unique assays have already been added to a common portfolio and colleagues from both businesses are working well together.
Mario Papillon, CEO of Cerba Research comments: “ This MoU is an important milestone with Teddy Lab which demonstrates our commitment to expand our footprint into new geographic territories and to best support our global biopharma customers in their evolving needs.
We organize all of the trending information in your field so you don't have to. Join 8,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content